Online telehealth company Hims and Hers Health is launching its weight-loss membership and treatment plans in the United ...

Novo Nordisk enters the final stretch of 2025 looking almost unrecognizable from the market darling it was just months ago.

As competitive as the obesity drug market has become, Novo Nordisk's decision to slash the prices of its GLP-1 agonist drugs could put it back on the right track. While profit margins may slip due to ...

The move into the UK weight-loss category has been facilitated by the acquisition earlier this year of Zava, a London-based ...

One of largest U.S. telehealth providers expects to ride wave of exploding demand for weight-loss drug semaglutide when it ...

Online telehealth company Hims and Hers Health HIMS.N is launching its weight-loss membership and treatment plans in the UK ...

For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

Hims and Hers first announced its expansion into Canada in early July, taking the opportunity as Danish pharmaceutical giant ...

The dramatic stock slump, which puts Novo Nordisk at a historically cheap valuation, reflects investor concern over future sales growth and competition, particularly from rival Eli Lilly & Co.

»Hvis håndhævelsen af reglerne i USA nu reelt er skiftet fra selskaberne (bl.a. Novo Nordisk) til myndighederne, vil det ...

Hims Hers Health Inc (NYSE:HIMS) stock fell 4.4% Wednesday after U.S. lawmakers introduced legislation that could ...